Breda, the Netherlands / Ghent, Belgium, 29 Oct 2015 - argenx (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Executive Officer, Tim Van Hauwermeiren and Chief Financial Officer, Eric Castaldi, will be participating in several upcoming investor conferences in November and December:
- 4th Annual KBC Securities Benelux Biotech & Healthcare Conference on Tuesday, November 10, 2015 in New York City.
- Stifel Healthcare Conference 2015 on Tuesday, November 17, 2015 in New York City with a corporate presentation.
- Jefferies 2015 Global Healthcare Conference on Thursday, November 19, 2015 in London.
- Bank Degroof Petercam Healthcare CEO Seminar on Wednesday, November 25, 2015 in Brussels.
- Piper Jaffray 27th Annual Healthcare Conference on Tuesday, December 1-2, 2015 in New York City with a corporate presentation.
Visit our new website: www.argenx.com
About argenx
argenx combines the diversity of the llama immune system with antibody engineering to advance a clinical pipeline to treat patients with cancer and autoimmune diseases. Our platforms allow us to unlock novel and complex targets and develop antibody-based drugs designed for longer duration of effect and greater efficacy. The strength of our team, our deep understanding of the biology, and our committed collaborations with industry leaders contribute to the success of our journey.
argenx is listed on the Euronext Brussels exchange under the symbol ARGX.
SIMPLE Antibody(TM) and NHance® are trademarks of arGEN-X NV
For further information, please contact:
Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 243 40 70
info@argenx.com
Mark Swallow/David Dible
Citigate Dewe Rogerson
+44 207 282 2948
arGEN-X@citigatedr.co.uk
Beth DelGiacco (US IR)
Stern Investor Relations
+1 212 362 1200
beth@sternir.com